At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed adenocarcinoma of prostate treated with radical prostatectomy
- ✓Adverse pathologic features: positive surgical margin, pT3-4, Gleason 8-10, or tertiary Gleason 5
- ✓Rising PSA on ≥2 consecutive draws exceeding 0.03 ng/mL
- ✓Intermediate- or high-risk Decipher genomic classifier score
- ✕Evidence of distant metastases
- ✕Neuroendocrine or small cell carcinoma histology
- ✕Prior pelvic radiotherapy
- ✕History of Crohn's disease, ulcerative colitis, or ataxia telangiectasia
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for Adjuvant or Salvage Treatment for Rising PSA After Radical Prostatectomy (EXCALIBUR)
In Brief
A Phase 2 clinical trial evaluating Hormone Therapy and Stereotactic Body Radiation Therapy for Prostate Adenocarcinoma and 5 related conditions. Currently recruiting, targeting 102 participants across 1 site.
Detailed Summary
This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
Study Details
Timeline
Interventions
Receive hormonal therapy
Undergo SBRT